Research and Markets: TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2015

Research and Markets (http://www.researchandmarkets.com/research/6kc27v/tnfalpha) has announced the addition of the "TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2015" report to their offering.

The TNF-alfa signaling pathway stimulates the MAPK signaling module and activates NFkB.

There are today 386 companies plus partners developing 507 TNF-alpha pathway targeting drugs in 2119 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 295 drugs.

Tnf-Alpha Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 270 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 264 out of the 266 studied drug targets so far have been recorded with somatic mutations.

The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 58 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Pipeline Breakdown According to Number of Drugs

• Marketed - 42
• Registered - 1
• Pre-registration - 5
• Phase III - 65
• Phase II - 199
• Phase I - 228
• Preclinical - 281
• No Data - 16
• Suspended - 6
• Ceased - 295

Delivery Format: Desktop App plus Online Access to Updates (One Year)

For more information visit http://www.researchandmarkets.com/research/6kc27v/tnfalpha